Breastcancer.org5 New Findings About GLP-1s and Breast Cancer

⚠️ Small Study / Early Comparative Evidence
A SABCS 2025 poster spotlight session synthesized five retrospective analyses examining GLP-1 receptor agonists in breast cancer populations. Findings spanned weight loss efficacy, mortality signals, chemotherapy tolerability, DCIS outcomes, and endocrine therapy side effects across hormone receptor-positive disease.

Clinical Considerations

• A 38-patient chart review found mean 17.4% body weight loss at 12 months with GLP-1s or other weight loss agents alongside endocrine therapy.
• Retrospective analysis of ~8,800 patients with obesity and breast cancer associated GLP-1 use with 46% lower all-cause mortality over 5.5 years; causality not established.
• Among 5,600+ patients receiving chemotherapy, GLP-1 use was associated with fewer reported anemia, neutropenia, neuropathy, and cardiomyopathy events.
• A DCIS cohort of 3,000+ patients showed 74% lower invasive or metastatic progression with GLP-1 use, though concurrent analysis flagged higher rates of endocrine therapy adverse effects including hot flashes and joint pain.

Practice Applications

• Recognize GLP-1 data in breast cancer as hypothesis-generating from retrospective conference posters.
• Interpret mortality and recurrence signals cautiously pending prospective validation.
• Monitor endocrine therapy tolerability in patients on concurrent GLP-1 agents.
• Avoid extrapolating these signals to clinical recommendations outside obesity management indications.

More in GLP-1s